Payment overview · 2025
General Payments
$1,036.11
56 reported records · 19 companies
Healthcare provider profile · identity verified
Eric C. Cox, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AMARILLO, TX · NPI 1578560231
Verified facts
What the public records show
CMS Open Payments records show Eric C. Cox, M.D. received $1,036.11 in general payments during 2025 across 56 reported records.
Phathom Pharmaceuticals, Inc. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $163.99 | 15.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $162.68 | 15.7% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.43 | 9.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $95.55 | 9.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.31 | 8.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.15 | 4.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.97 | 4.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $41.89 | 4.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.66 | 3.7% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $38.16 | 3.7% | 2 | 2025 |
| INTERNATIONAL REHABILITATIVE SCIENCES, INC | Unresolved — no canonical attribution shown | $32.11 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.93 | 3.0% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $26.96 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.84 | 2.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.38 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.53 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.08 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.72 | 1.5% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $14.77 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,036.11 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $163.99 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $115.61 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $95.55 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $76.59 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.73 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $47.07 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.97 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $41.89 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.94 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| RS-4i Plus with Intersperse Normalized: rs 4i plus with intersperse |
Device | INTERNATIONAL REHABILITATIVE SCIENCES, INC | $32.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.93 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.93 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $11.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 135 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
135 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 517 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 497 | 128 |
| Gabapentin | Gabapentin | 471 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 102 |
| Meloxicam | Meloxicam | 386 | 84 |
| Lisinopril | Lisinopril | 335 | 87 |
| Metformin Hcl | Metformin Hcl | 306 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 284 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 69 |
| Omeprazole | Omeprazole | 252 | 69 |
| Allopurinol | Allopurinol | 246 | 50 |
| Tramadol Hcl | Tramadol Hcl | 216 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 48 |
| Losartan Potassium | Losartan Potassium | 209 | 53 |
| Montelukast Sodium | Montelukast Sodium | 173 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 171 | 32 |
| Progesterone | Progesterone, Micronized | 168 | 28 |
| Simvastatin | Simvastatin | 167 | 43 |
| Alprazolam | Alprazolam | 163 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 41 |
| Ozempic | Semaglutide | 153 | 31 |
| Furosemide | Furosemide | 148 | 30 |
| Sertraline Hcl | Sertraline Hcl | 147 | 28 |
| Estradiol | Estradiol | 142 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 138 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 36 |
| Donepezil Hcl | Donepezil Hcl | 136 | 31 |
| Metformin Hcl Er | Metformin Hcl | 136 | 37 |
| Liothyronine Sodium | Liothyronine Sodium | 135 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 135 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 132 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 33 |
| Trazodone Hcl | Trazodone Hcl | 128 | 35 |
| Celecoxib | Celecoxib | 123 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 24 |
| Potassium Chloride | Potassium Chloride | 119 | 30 |
| Azithromycin | Azithromycin | 108 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 28 |
| Prednisone | Prednisone | 100 | 76 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 95 | 29 |
| Pregabalin | Pregabalin | 86 | 16 |
| Eliquis | Apixaban | 85 | 14 |
| Propranolol Hcl | Propranolol Hcl | 84 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 22 |
| Jardiance | Empagliflozin | 80 | 14 |
| Carvedilol | Carvedilol | 79 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 17 |
| Mounjaro | Tirzepatide | 77 | 11 |
| Lorazepam | Lorazepam | 75 | 22 |
| Bupropion Xl | Bupropion Hcl | 69 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 18 |
| Glimepiride | Glimepiride | 63 | 17 |
| Memantine Hcl | Memantine Hcl | 62 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 18 |
| Temazepam | Temazepam | 60 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 60 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 55 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 14 |
| Fenofibrate | Fenofibrate | 49 | 13 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 47 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 14 |
| Methocarbamol | Methocarbamol | 46 | 13 |
| Irbesartan | Irbesartan | 45 | suppressed |
| Spironolactone | Spironolactone | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 32 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Glipizide | Glipizide | 37 | 12 |
| Linzess | Linaclotide | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 12 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Diazepam | Diazepam | 33 | 11 |
| Fluconazole | Fluconazole | 33 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Armour Thyroid | Thyroid,pork | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Np Thyroid | Thyroid,pork | 27 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 12 |
| Tolterodine Tartrate | Tolterodine Tartrate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Epinephrine | Epinephrine | 21 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,036.11 · 56 records | Phathom Pharmaceuticals, Inc. | AIRSUPRA, AREXVY, Auvelity, BEXSERO, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Leqembi, MOUNJARO, NEFFY, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, RS-4i Plus with Intersperse, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error